The US Food and Drug Administration’s Richard Pazdur does not come into an Oncologic Drugs Advisory Committee meeting with his mind made up on what regulatory action the agency is going to take on a cancer drug application.
Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts
Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.
